Search results

20 items matching your search terms.
Filter the results.
Item type













New items since



Sort by relevance · date (newest first) · alphabetically
Eligible for breast conserving therapy, many still choose mastectomy
New treatment strategies have given more triple-negative breast cancer patients the choice of breast-conserving surgery. But research led by Brigham and Women's Hospital, in collaboration with UNC Lineberger member David Ollila, MD, has shown that even when given the choice, more than 30 percent of patients still chose to have a complete breast removal via mastectomy.
Located in News
Early menarche may be important in development of aggressive breast cancer in African-American women
A multicenter research team known as the African American Breast Cancer Epidemiology and Risk Consortium (AMBER), which includes UNC Lineberger's Andrew Olshan, PhD has uncovered differences in ER-positive & ER-negative breast cancer pathways. The team examined whether relationships between age at menarche and breast cancer are the same for tumors that are ER-positive or ER-negative, particularly among African-American women. ER-negative breast cancer is generally more aggressive and known to be associated with a poorer prognosis than ER-positive disease.
Located in News
Rock stars for a day
As a breast cancer survivor, Barbara Martin has established a tradition – walking 39 miles to raise awareness and funds for breast cancer – that has become very special to her. This challenge became even more special this year, as her mother and daughter were both by her side along the way.
Located in News
UNC Lineberger-led study tests drug strategy for aggressive breast cancer in the brain
Results from a UNC Lineberger-led study were published Monday in the journal Molecular Cancer Therapeutics. The pre-clinical study was the first to investigate one particular drug strategy as a treatment for breast cancer after it's spread to the brain.
Located in News
Who says you can’t go home?
Amy Charney had already registered to run the 2015 Boston Marathon when she was told she had breast cancer. But not even that diagnosis and active treatment would keep her from crossing the finish line in her hometown of Boston.
Located in News
Perou recognized as health care innovator, awarded Triangle Business Journal honor
Charles M. Perou, PhD, professor of genetics and pathology at the University of North Carolina School of Medicine and the basic science leader of the UNC Lineberger Comprehensive Cancer Center Breast Cancer Research Program, has been acknowledged as a health care innovator by the Triangle Business Journal. During an awards ceremony on Thursday, Perou was selected from a pool of candidates as the finalist in the 2015 TBJ Health Care Heroes – Innovator category.
Located in News
Potential drug target identified for aggressive breast cancer type
In a new pre-clinical study published today, UNC Lineberger researchers show that they can exploit cancer’s reliance on a particular protein to help fight triple negative breast cancer. They believe the protein could be a potential new drug target.
Located in News
UNC Lineberger breast cancer researcher wins ASCO foundation grant
Katherine Reeder-Hayes, MD, MBA, Msc, a UNC Lineberger member and a clinical assistant professor in the University of North Carolina School of Medicine, won a Career Development Award from the Conquer Cancer Foundation of the American Society of Clinical Oncology. She was one of 11 clinical investigators chosen to receive the three-year award, which goes to researcher-physicians to help them build independent clinical research programs.
Located in News
Melissa Troester, PhD – Team Science at its Best
UNC Lineberger member Melissa Troester, PhD, values a team approach in her work and her personal life. As co-leader of the cancer center’s Cancer Epidemiology Program, Troester’s work is an important part of UNC Lineberger’s interdisciplinary research on the causes of breast cancer and the translational research on strategies of prevention, treatment and cure.
Located in News
Researchers find new approach to treat drug-resistant HER2-positive breast cancer
Using human cancer cell lines, UNC scientists identified various ways that HER2-positive breast cancer tumors resist therapy, and they discovered a potential combination therapy to overcome multiple mechanisms of resistance and kill cancer cells.
Located in News